MBX Biosciences (MBX) Receivables - Other (2023 - 2026)
MBX Biosciences (MBX) posted Receivables - Other of $3.2 million for Q1 2026, up 48.92% sequentially from $2.1 million in Q4 2025, and up 127.94% YoY from $1.4 million in Q1 2025.
MBX Biosciences (MBX) Receivables - Other (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Receivables - Other for 4 years, with the latest figure at $3.2 million in Q1 2026.
- Quarterly Receivables - Other rose 127.94% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 127.94% YoY) and the FY2025 annual result came in at $2.1 million, up 210.85% from the prior year.
- Receivables - Other climbed to $3.2 million in Q1 2026 per MBX's latest filing, from $2.1 million in the prior quarter.
- Over five years, Receivables - Other peaked at $3.2 million in Q1 2026 and troughed at $208000.0 in Q4 2023.
- A 4-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other surged 227.88% in 2024, then jumped 80.42% in 2025.
- Over 4 years, Receivables - Other stood at $208000.0 in 2023, then soared by 227.88% to $682000.0 in 2024, then jumped by 210.85% to $2.1 million in 2025, then surged by 48.92% to $3.2 million in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $3.2 million, $2.1 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.04 Mn |
| Jun 30, 2026 | 3.04 Mn |
| Mar 31, 2026 | 3.16 Mn |
| Mar 31, 2026 | 3.16 Mn |
| Dec 31, 2025 | 2.12 Mn |
| Dec 31, 2025 | 2.12 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 841,000.00 |
| Jun 30, 2025 | 841,000.00 |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 682,000.00 |
| Dec 31, 2024 | 682,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Dec 31, 2023 | 208,000.00 |
| Dec 31, 2023 | 208,000.00 |